- Details
- (Length of Conversation: 22 mins) Download slides J. Kellogg Parsons MD, talks with Alicia Morgans prior to his presentation of The Men’s Eating and Living (MEAL) Study (CALGB 70807 [Alliance]): A Randomized Clinical Trial of a Diet Intervention in Men on Active Surveillance for Prostate Cancer at the 113th Annual Scientific Meeting of the American Urological Association (AUA) . A much anticipated...
|
- Details
- (Length of Presentation: 20 min) Jehonathan Pinthus presents the role of androgen deprivation therapy (ADT) in promoting cardiovascular disease (CVD) and focuses on two prospective studies, one of which is embedded in the other. The Role of Androgen Deprivation Therapy in Cardiovascular Disease – A Longitudinal Prostate Cancer Study (RADICAL PC1) is a prospective cohort study of men within one yea...
|
- Details
- (Length of Discussion: 21 min) Tom Keane brings new concepts in androgen deprivation therapy (ADT) to light specifically discussing agonists versus antagonists, new androgen receptor-targeted drugs, including immunotherapy biomarkers, and genomic testing. He reviews the current state of the CRPC treatment and ADT options for use in advanced metastatic disease and concludes with a discussion on tre...
|
- Details
- (Length of Conversation: 7 min) Alicia Morgans, MD and Charles Ryan, MD discuss the quality of life between patients with metastatic hormone-sensitive prostate cancer who were treated with ADT+docetaxel and those who were treated with ADT alone. The importance of the study was to understand how different treatments actually affected the individuals receiving them. Biographies: Alicia Morgans, MD,...
|
- Details
- (Length of Conversation: 19 min) Mary-Ellen Taplin, MD, and Alicia Morgans, MD discuss the topic of neoadjuvant therapy for men with high-risk disease prior to surgery, specifically, prior to prostatectomy. Among the topics discussed include the importance of studying neoadjuvant chemotherapy and hormonal therapies in clinical trials before being used more broadly in everyday clinical practice, pa...
|
- Details
- (Length of Discussion: 4 min) Dr. Thomas Keane provides a commentary on the The FALCON Trial , the impact of 18F-fluciclovine PET/CT on clinical management choices for men with biochemically recurrent prostate cancer presented at the recent 2018 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium . Eugene Jueren Teoh, MBBS, MRCP from the University of Oxford presented t...
|
- Details
- Dr. Baris Turkbey, Associate Research Physician of the Molecular Imaging Program at the National Cancer Institute, shares the past, present, and future approaches to prostate biopsies. Dr. Turkbey states that TRUS (Transrectal Ultrasound aka Systemic) biopsies have been the “standard of care” after PSA elevation for the past 25 years. However, prostate imaging is not always preceding biopsy. MRI p...
|
- Details
- (Length of Discussion: 17 min) Daniel George, MD and Director of GU Oncology talks with Alicia Morgans, MD about the IRONMAN initiative. The intent of the project was to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of a minimum of 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC...
|
- Details
- (Length of lecture - 19 minutes) Dr. Neal Shore addresses both the perception and evidence of side effect for patients on androgen deprivation therapy (ADT). There is a growing concern about ADT side effects now that it is being used more in non-metastatic prostate cancer, which is exposing men to ADT for longer periods of time. Several common adverse effects are known about ADT impacting multiple...
|
- Details
- (Length of Discussion: 25 min) Alicia Morgans, MD presents on the topic of biomarker development in advanced prostate cancer. In her presentation, Dr. Morgans discusses the difference between predictive and prognostic biomarkers and the importance of understanding the purpose of each. Also, Dr. Morgans identifies clinical biomarkers for men with mCRPC who are undergoing treatment with docetaxel. L...
|
